|
When thinking of valorisation, one can think of the exploitation of an invention: a new drug target, a apparatus, a procedure which is commercially applicable. However, within the UMC’s other types of valorisation occur as well. For example, the combination of knowledge and biological materials, a so called biobank, can be of high value to companies. They can be used for the development of new drugs. Exploiting can then be in the form of third party research (contract research), or the UMC can start an own company in which the research activities concerning the biobank can be exploited.
|